P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
about
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceStereoselective Regulation of P-gp Activity by Clausenamide Enantiomers in Caco-2, KB/KBv and Brain Microvessel Endothelial CellsBlood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative DiseasesSmall molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.Pathways for small molecule delivery to the central nervous system across the blood-brain barrier.Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approachAn in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats.Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrierDistribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active effluxEstrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasThe role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier.17-β-Estradiol: a powerful modulator of blood-brain barrier BCRP activity.Rapid detection of ABC transporter interaction: potential utility in pharmacology.The challenge of exploiting ABCG2 in the clinic.Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upBrain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearanceBrain distribution of cediranib is limited by active efflux at the blood-brain barrier.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout miceABC Transporters and the Alzheimer's Disease Enigma.Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.Improving cancer chemotherapy with modulators of ABC drug transporters.Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease.Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.Reversing multidrug resistance by tyrosine kinase inhibitorsDelivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
P2860
Q26865927-3896BF36-E925-4D86-8A6A-1E3EA93DF010Q28547401-77D6687A-6199-424A-BEB4-9C7352164A6CQ28829017-4876894F-147F-44F3-86AD-1684CC2CC45EQ30664269-FF576B1B-920D-43B7-A51A-A6246399DA35Q33783748-F28A6B3F-604D-42B6-A7AF-6FA4793AEBBAQ33863299-D3976138-FDEC-4900-88F9-9326BBCEE6D5Q33876743-8538CBCE-26D1-473F-AED6-9BD1F67A44CFQ33900889-720EC9D8-CB99-4927-8E7D-B29232D15048Q34028148-EF5259B6-53F6-476F-9D37-057E78EF9F41Q34035224-E97687A8-E6B2-4037-907A-8D89FBC3D46EQ34121339-AE33DC65-C661-458D-B75A-633121FFE920Q34231554-C2B67529-AC54-4A2A-BC41-87FA2CFE867CQ34458602-523ED9B0-109A-46FC-846A-2C8549A98280Q34502705-1880A6D9-C400-49A8-BAE4-DEB8866ABA07Q34502756-56A2D9DA-B757-477C-B351-E7D03F3944FDQ34913068-7A23FAD2-4057-49F8-851A-520995AB5BAFQ34968909-DCD30FBF-F18D-4BA6-96F5-BCB6B0F1D083Q34970234-B3FA320F-FE75-4B7E-A7CC-C33E430ABA11Q35126258-C3AD42CF-E9F6-4A6A-9BC8-9B5F6AFB8523Q35171274-4B601D87-D359-4089-9CBE-FA8FB8D5BB02Q35708124-EAB76FFF-CC34-461C-AD67-75DBA6E56BE8Q35720625-CFFC0D5F-25C2-476D-AB7C-EC57844A8F20Q35743315-4A508BBC-0CAB-4CA9-B707-01AE050918F5Q35810745-FFAE59E8-7B13-4473-AD6F-10E23727F77EQ35913169-9E0ED6FB-8FF2-4562-81EA-E9033D77A52AQ35946822-54B6A218-BAC3-44F5-AC42-02E45C644089Q35996449-084BD1A9-72DC-40F9-997B-7E9D69D619E6Q36005085-F8064018-DB5F-4F41-92C6-2C2EEC8412EFQ36057973-30437EBB-8A97-4A46-8DD2-BE8E1FBCDCC4Q36105340-4F45867B-BA69-423D-B80E-A8903DC17463Q36108251-AA47B0FC-D745-4C7D-85BE-29BB66860245Q36212765-A9F4D6E2-1FE4-4728-8DB7-8D96DE005D8BQ36312901-8DF11EB3-801C-4317-A77D-E2D943AA3E38Q36339666-9C3FADE3-CC18-4D73-8860-AB16B0A20550Q36497633-2AE64B24-D31D-4230-BD6F-AB871863F686Q36613936-082C6F19-768D-4E54-AAAC-9D17AA06D4AAQ36717122-BFD07ECD-B875-42A8-B7E1-887229FAFE85Q36918220-FF4DF81D-CC08-4EF2-BF64-909D3D9BAD84Q37183670-87FC78E8-58D3-4038-9DEC-B30F88688411Q37308322-4C479EAA-3CD4-4DEA-80A5-8124DA6C53A7
P2860
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
P-glycoprotein and breast canc ...... ain distribution of dasatinib.
@en
P-glycoprotein and breast canc ...... ain distribution of dasatinib.
@nl
type
label
P-glycoprotein and breast canc ...... ain distribution of dasatinib.
@en
P-glycoprotein and breast canc ...... ain distribution of dasatinib.
@nl
prefLabel
P-glycoprotein and breast canc ...... ain distribution of dasatinib.
@en
P-glycoprotein and breast canc ...... ain distribution of dasatinib.
@nl
P2093
P356
P1476
P-glycoprotein and breast canc ...... ain distribution of dasatinib.
@en
P2093
Cliff Chen
Naveed M Shaik
Sagar Agarwal
William F Elmquist
Zheng Yang
P304
P356
10.1124/JPET.109.154781
P407
P577
2009-06-02T00:00:00Z